After a thorough and comprehensive review of proposals received from suppliers of viral marker testing platforms and assays, CTS has decided to convert to the Ortho VERSEIA Integrated Processor (VIP) viral marker testing platform and associated assays in January 2021. An exact conversion date will be provided when available. We are confident that the VERSIA system will allow us to continue delivering on our commitment to support our clients in their life-saving mission.
Read all about it on the Communication page by clicking this link: Communications
In July, all 5 CTS laboratories will convert from the current Grifols Ultrio Plus NAT triplex assay ...
On September 14, 2020, our Phoenix laboratory began performing a portion of our alternate donor anti...
CTS Dallas and Phoenix Labs successfully implemented WNV NAT testing on the Panther Testing Platform...
CTS will be revising some forms in use by clients on October 26, 2020. We do try to limit form chang...
A new Learning Center website will launch on Monday, March 30, 2020. While the link to the new Learn...
The recent communication regarding the recent Anti-SARS-CoV-2 Total assay in Tampa has brought about...